Encompass Health Corporation $EHC Shares Sold by Vestmark Advisory Solutions Inc.

Vestmark Advisory Solutions Inc. lessened its stake in shares of Encompass Health Corporation (NYSE:EHC) by 50.6% during the second quarter, Holdings Channel.com reports. The fund owned 2,240 shares of the company’s stock after selling 2,298 shares during the period. Vestmark Advisory Solutions Inc.’s holdings in Encompass Health were worth $275,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Intech Investment Management LLC grew its stake in Encompass Health by 21.8% during the 1st quarter. Intech Investment Management LLC now owns 21,329 shares of the company’s stock valued at $2,160,000 after acquiring an additional 3,815 shares in the last quarter. Park Avenue Securities LLC increased its stake in Encompass Health by 28.5% in the 2nd quarter. Park Avenue Securities LLC now owns 9,153 shares of the company’s stock valued at $1,122,000 after buying an additional 2,030 shares during the period. Ballentine Partners LLC purchased a new stake in Encompass Health in the 2nd quarter worth approximately $301,000. Whalen Wealth Management Inc. purchased a new position in shares of Encompass Health during the 2nd quarter valued at $644,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Encompass Health by 6.2% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 390,494 shares of the company’s stock worth $39,549,000 after acquiring an additional 22,896 shares in the last quarter. 97.25% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Encompass Health

In other news, EVP Patrick William Tuer sold 1,020 shares of Encompass Health stock in a transaction dated Wednesday, August 27th. The shares were sold at an average price of $123.59, for a total transaction of $126,061.80. Following the completion of the transaction, the executive vice president directly owned 18,846 shares in the company, valued at $2,329,177.14. This trade represents a 5.13% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 2.00% of the company’s stock.

Encompass Health Price Performance

NYSE:EHC opened at $114.76 on Thursday. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.06 and a current ratio of 1.06. Encompass Health Corporation has a 52 week low of $87.85 and a 52 week high of $127.99. The firm’s 50-day simple moving average is $123.08 and its 200 day simple moving average is $119.72. The firm has a market cap of $11.55 billion, a price-to-earnings ratio of 21.70, a P/E/G ratio of 2.20 and a beta of 0.91.

Encompass Health (NYSE:EHC) last posted its earnings results on Wednesday, March 16th. The company reported $0.93 earnings per share for the quarter. The firm had revenue of $136.30 million for the quarter. Encompass Health had a net margin of 9.33% and a return on equity of 18.19%. Encompass Health has set its FY22 guidance at $3.83-$4.19 EPS. As a group, sell-side analysts predict that Encompass Health Corporation will post 4.8 earnings per share for the current year.

Encompass Health Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, January 15th. Investors of record on Friday, January 2nd will be given a dividend of $0.19 per share. This represents a $0.76 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date is Friday, January 2nd. Encompass Health’s payout ratio is presently 14.37%.

Wall Street Analysts Forecast Growth

EHC has been the subject of a number of recent research reports. Zacks Research raised Encompass Health from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, October 21st. UBS Group raised their price target on shares of Encompass Health from $140.00 to $150.00 and gave the company a “buy” rating in a report on Thursday, October 2nd. KeyCorp increased their target price on shares of Encompass Health from $135.00 to $140.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 16th. Weiss Ratings reiterated a “buy (b+)” rating on shares of Encompass Health in a research note on Wednesday, October 8th. Finally, Barclays upped their target price on Encompass Health from $141.00 to $150.00 and gave the stock an “overweight” rating in a research report on Thursday, October 30th. Three analysts have rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $142.86.

Encompass Health Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.